Literature DB >> 3849317

Platelet-adjusted IFN dosage in the treatment of advanced hairy cell leukemia.

F Porzsolt, J Thomä, M Unsöld, W Wolf, H J Obert, B Kubanek, H Heimpel.   

Abstract

It has been demonstrated that hairy cell leukemia (HCL) can be efficiently treated by various preparations of alpha interferons (IFN). Nevertheless, there are several open questions, such as the route, mode and dosage of IFN application. These variables of IFN treatment may be critical since a myelosuppressive effect of IFN, which is commonly seen in the initial phase of treatment, can result in further deterioration of the already impaired platelet production in advanced HCL. The present study shows that serious side effects can be avoided and the flu-like syndromes described by others almost completely reduced by s.c. application of IFN via a portable pump during a daily 8 h period. IFN is initially given five times a week and the daily dose is adjusted according to the actual platelet count. The efficiency controls show that the increase of platelets in the peripheral blood, which is most critical in advanced HCL, may be seen earlier by this than by other protocols, which usually recommend higher daily doses of IFN and only three instead of five weekly applications.

Entities:  

Mesh:

Substances:

Year:  1985        PMID: 3849317     DOI: 10.1007/bf00320115

Source DB:  PubMed          Journal:  Blut        ISSN: 0006-5242


  6 in total

1.  Treatment of hairy-cell leukaemia with recombinant human alpha 2-interferon.

Authors:  J T Janssen; B E de Pauw; R S Holdrinet
Journal:  Lancet       Date:  1984-05-05       Impact factor: 79.321

2.  Prognosis and therapy in hairy cell leukemia.

Authors:  J Jansen; G J den Ottolander; R S Holdrinet; G J Tricot; J Hermans
Journal:  Semin Oncol       Date:  1984-12       Impact factor: 4.929

3.  Hairy cell leukemia: clinical presentation and follow-up of 211 patients.

Authors:  G Flandrin; F Sigaux; G Sebahoun; P Bouffette
Journal:  Semin Oncol       Date:  1984-12       Impact factor: 4.929

4.  Alpha interferon for induction of remission in hairy-cell leukemia.

Authors:  J R Quesada; J Reuben; J T Manning; E M Hersh; J U Gutterman
Journal:  N Engl J Med       Date:  1984-01-05       Impact factor: 91.245

5.  Hairy cell leukemia (HCL) variant: an intermediate disease between HCL and B prolymphocytic leukemia.

Authors:  D Catovsky; M O'Brien; J V Melo; J Wardle; M Brozovic
Journal:  Semin Oncol       Date:  1984-12       Impact factor: 4.929

6.  Treatment with low dose human recombinant interferon-alpha-2-ARG induces complete remission in patients with hairy cell leukemia.

Authors:  G Gastl; H Denz; C Abbrederis; H Huber; J Troppmair; J Wiegele; D Niederwieser; R Flener; C Huber
Journal:  Onkologie       Date:  1985-06
  6 in total
  6 in total

1.  The effect of interferons on cellular differentiation.

Authors:  T Moritz; H Kirchner
Journal:  Blut       Date:  1986-11

Review 2.  Palliative therapies in elderly cancer patients.

Authors:  F Porzsolt; J Zeeh; D Platt
Journal:  Drugs Aging       Date:  1995-03       Impact factor: 3.923

3.  Primary treatment of hairy cell leukemia: should IFN-therapy replace splenectomy?

Authors:  F Porzsolt
Journal:  Blut       Date:  1986-05

4.  [Effectiveness of gamma interferon and alpha interferon in hairy cell leukemia].

Authors:  N Niederle; C Doberauer; O Kloke; K Höffken; C G Schmidt
Journal:  Klin Wochenschr       Date:  1987-07-15

5.  Deficient IFN alpha production in hairy cell leukemia.

Authors:  F Porzsolt; R Janik; G Heil; O Brudler; A Raghavachar; S Scholz; U Papendick; H Heimpel
Journal:  Blut       Date:  1986-03

6.  Alpha-interferon treatment for adult T cell leukemia: low levels of circulating alpha-interferon and it's clinical effectiveness.

Authors:  K Saigo; S Shiozawa; K Shiozawa; J Wakuya; K Ueda; N Yamaguchi; H Shibata; T Masaoka
Journal:  Blut       Date:  1988-02
  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.